Adaptive Biotechnologies Corporation
ADPT
Classement en actions
#4167
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in... Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
Prix de l'action
$24.09
Dernière synchronisation: 2026-10-16
Capitalisation boursière
$3.84B
Changement (1 jour)
-5.82%
Changement (1 an)
47.79%
Pays
US
Échange Adaptive Biotechnologies Corporation (ADPT)
Catégorie
Healthcare
Marge opérationnelle de Adaptive Biotechnologies Corporation (ADPT)
Marge opérationnelle au October 2026 TTM : -12.16%
Selon les derniers rapports financiers et le cours de l'action de Adaptive Biotechnologies Corporation, la marge opérationnelle actuelle (TTM) est de -12.16%. À la fin de 2024, elle était de -90.83%.
Historique de la marge opérationnelle pour Adaptive Biotechnologies Corporation de 2017 à 2026
Marge opérationnelle à la fin de chaque année
| Année | Marge opérationnelle | Changez |
|---|---|---|
| 2026 (TTM) | -12.16% | -41.03% |
| 2025 | -20.62% | -77.30% |
| 2024 | -90.83% | -31.88% |
| 2023 | -133.33% | 23.42% |
| 2022 | -108.03% | -20.21% |
| 2021 | -135.39% | -12.84% |
| 2020 | -155.33% | 68.56% |
| 2019 | -92.15% | 3.09% |
| 2018 | -89.39% | -22.73% |
| 2017 | -115.68% | 0.00% |
Marge opérationnelle pour des entreprises similaires ou concurrentes
| Entreprise | Marge opérationnelle | Différence de Marge Opérationnelle | Pays |
|---|---|---|---|
| 38.59% | -103.17% |
US
|
|
| -149.01% | -87.75% |
US
|
|
| 25.57% | -102.10% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -102.37% |
NL
|
Qu'est-ce que la Marge opérationnelle d'une entreprise ?
La Marge opérationnelle est un indicateur clé pour évaluer la rentabilité d'une entreprise. Une marge d'exploitation plus élevée est généralement préférable car elle montre qu'une entreprise peut vendre ses produits ou services bien au-dessus de leurs coûts de production. Elle se calcule en divisant les bénéfices par le chiffre d'affaires.